Quarterly report pursuant to Section 13 or 15(d)

Consolidated Statements of Changes in Stockholders' Equity (Deficit)

v3.21.1
Consolidated Statements of Changes in Stockholders' Equity (Deficit) - USD ($)
Common Stock
Additional Paid-in Capital
Accumulated Deficit
Total
Balance at the beginning of the period at Sep. 30, 2019 $ 172,612 $ 37,885,151 $ (38,865,060) $ (807,297)
Balance at the beginning of the period (in shares) at Sep. 30, 2019 172,612,233      
Net loss $ 0 0 (2,391,638) (2,391,638)
Issuance of common stock and warrants, net of financing costs $ 14,286 2,152,876 0 2,167,162
Issuance of common stock and warrants, net of financing costs (in shares) 14,285,714      
Issuance of restricted stock $ 0 0 0 0
Stock based compensation expense 0 496,255 0 496,255
Balance at the ending of the period at Mar. 31, 2020 $ 186,898 40,534,282 (41,256,698) (535,518)
Balance at the ending of the period (in shares) at Mar. 31, 2020 186,897,947      
Balance at the beginning of the period at Dec. 31, 2019 $ 186,898 40,237,079 (40,524,814) (100,837)
Balance at the beginning of the period (in shares) at Dec. 31, 2019 186,897,947      
Net loss $ 0 0 (731,884) (731,884)
Stock based compensation expense 0 297,203 0 297,203
Balance at the ending of the period at Mar. 31, 2020 $ 186,898 40,534,282 (41,256,698) (535,518)
Balance at the ending of the period (in shares) at Mar. 31, 2020 186,897,947      
Balance at the beginning of the period at Sep. 30, 2020 $ 193,045 41,862,901 (43,556,437) $ (1,500,491)
Balance at the beginning of the period (in shares) at Sep. 30, 2020 193,044,766     193,044,766
Net loss $ 0 0 (2,945,400) $ (2,945,400)
Issuance of common stock and warrants, net of financing costs $ 43,125 6,176,108 0 6,219,233
Issuance of common stock and warrants, net of financing costs (in shares) 43,125,004      
Issuance of restricted stock $ 550 (550) 0 0
Issuance of restricted stock (in shares) 550,000      
Stock based compensation expense $ 0 278,340 0 278,340
Balance at the ending of the period at Mar. 31, 2021 $ 236,720 48,316,799 (46,501,837) $ 2,051,682
Balance at the ending of the period (in shares) at Mar. 31, 2021 236,719,770     236,719,770
Balance at the beginning of the period at Dec. 31, 2020 $ 193,045 41,948,512 (44,710,541) $ (2,568,984)
Balance at the beginning of the period (in shares) at Dec. 31, 2020 193,044,766      
Net loss $ 0 0 (1,791,296) (1,791,296)
Issuance of common stock and warrants, net of financing costs $ 43,125 6,176,108 0 6,219,233
Issuance of common stock and warrants, net of financing costs (in shares) 43,125,004      
Issuance of restricted stock $ 550 (550) 0  
Issuance of restricted stock (in shares) 550,000      
Stock based compensation expense $ 0 192,729 0 192,729
Balance at the ending of the period at Mar. 31, 2021 $ 236,720 $ 48,316,799 $ (46,501,837) $ 2,051,682
Balance at the ending of the period (in shares) at Mar. 31, 2021 236,719,770     236,719,770